Fixing genes won’t fix us
By Jim Kozubek,
Boston Globe
| 06. 01. 2017
Methadone Mile is a stretch of road along Massachusetts Avenue that begins in the South End and stretches north to the Charles River. On the other side of the river is Cambridge. For the past few years, I lived far north on this road in a $600-a-month room in a house with red paint peeling from its front clapboards. I was employed as a data scientist at the Brigham and Women’s Hospital, walking that Avenue each morning and afternoon through people in various stages of despondence, some fallen on the sidewalk, to one of my offices at the Broad Institute of MIT and Harvard.
Cambridge installed a half-million-dollar toilet near Mass. Ave in Harvard Square a year and a half ago, but that was to keep troubled people out of cafes. The big money is going toward a much different approach to longstanding social and public-health problems. Not far away, the really big, beautiful structures keep sprouting out of the ground, including Novartis’ recently completed $600 million campus, and the neighboring $1.4 billion Broad Institute with its 11 floors of...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...